Key facts
- This page summarizes Robert E. Conway's Form 4 filing for ARCA biopharma, Inc. (ORKA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 31 Jan 2024, 16:25.
Robert E. Conway - 30 Jan 2024 Form 4 Insider Report for ARCA biopharma, Inc. (ORKA)
- Reporting relationship
- Director, Chairman of the Board
- Issuer ticker
- ORKA
- Reported as of
- 30 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 31 Jan 2024, 16:25:24 UTC
- Prior SEC filing
- 04 Jan 2024
- Next SEC filing
- 20 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ C. Jeffrey Dekker, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Conway filed Form 4 for ARCA biopharma, Inc. (ORKA) on 31 Jan 2024.
Change
- Previous filing in this sequence was filed on 04 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABIO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 50,000
- Date
- 30 Jan 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABIO
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +6,000
- Change %
- Price
- $0.000000
- Shares after
- 6,000
- Date
- 30 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,000
- Exercise price
- $1.64
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.